购物车
- 全部删除
- 您的购物车当前为空
LSN3074753是LY3009120的类药物,属于泛RAF和Raf二聚体抑制剂。该化合物抑制活性主要针对因BRAF单体或RAF二聚体过度活化的MAPK通路导致的肿瘤细胞,尤其是带有BRAF或KRAS突变的结直肠癌细胞。此外,LSN3074753与Cetuximab合用于结直肠癌PDX模型,显示出显著的加成效应和协同作用,特别是在存在KRAS或BRAF突变的模型中。
LSN3074753是LY3009120的类药物,属于泛RAF和Raf二聚体抑制剂。该化合物抑制活性主要针对因BRAF单体或RAF二聚体过度活化的MAPK通路导致的肿瘤细胞,尤其是带有BRAF或KRAS突变的结直肠癌细胞。此外,LSN3074753与Cetuximab合用于结直肠癌PDX模型,显示出显著的加成效应和协同作用,特别是在存在KRAS或BRAF突变的模型中。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations. |
分子量 | 439.53 |
分子式 | C24H30FN5O2 |
CAS No. | 1455031-68-1 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容